Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
AVBP 
ArriVent BioPharma, Inc. Common Stock (AVBP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/27/2026: AVBP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $40.25
1 Year Target Price $40.25
| 6 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 958.97M USD | Price to earnings Ratio - | 1Y Target Price 40.25 |
Price to earnings Ratio - | 1Y Target Price 40.25 | ||
Volume (30-day avg) 7 | Beta 1.03 | 52 Weeks Range 15.47 - 26.00 | Updated Date 02/27/2026 |
52 Weeks Range 15.47 - 26.00 | Updated Date 02/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.15 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32.78% | Return on Equity (TTM) -51.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 528324215 | Price to Sales(TTM) - |
Enterprise Value 528324215 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 41281361 | Shares Floating 22608150 |
Shares Outstanding 41281361 | Shares Floating 22608150 | ||
Percent Insiders 3.13 | Percent Institutions 103.03 |
Upturn AI SWOT
ArriVent BioPharma, Inc. Common Stock
Company Overview
History and Background
ArriVent BioPharma, Inc. was founded in 2021. It is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for patients with significant unmet medical needs, particularly in the areas of pulmonary and rare diseases. A key milestone was its public offering in February 2023, which provided capital for advancing its pipeline.
Core Business Areas
- Pulmonary Diseases: ArriVent is developing novel therapies targeting severe respiratory and pulmonary diseases, aiming to address conditions with limited treatment options.
- Rare Diseases: The company also focuses on developing treatments for rare diseases, leveraging its scientific expertise to create impactful solutions for underserved patient populations.
Leadership and Structure
ArriVent BioPharma is led by a management team with extensive experience in drug development and commercialization. The exact organizational structure is typical of a biopharmaceutical company, with departments for research and development, clinical operations, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- Product Name 1: AVR-RD-01 (Sotatercept variant) - Description: ArriVent is developing AVR-RD-01, a novel fusion protein designed to rebalance growth factor signaling pathways implicated in pulmonary arterial hypertension (PAH). Market Share Data: Not applicable at this pre-commercial stage. Competitors: Bristol Myers Squibb (Macitentan), United Therapeutics (Uptravi), Bayer (Adempas), Pfizer (Revatio).
- Product Name 2: AVR-421 - Description: A small molecule inhibitor targeting a specific pathway involved in fibrotic lung diseases. Market Share Data: Not applicable at this pre-commercial stage. Competitors: Boehringer Ingelheim (Ofev), Genentech (Esbriet).
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in the areas of rare diseases and pulmonary conditions, is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. There is a strong demand for innovative therapies that address unmet medical needs, driving investment and scientific advancement. The market is competitive, with both large pharmaceutical companies and smaller biotechnology firms vying for breakthroughs.
Positioning
ArriVent BioPharma positions itself as a focused biopharmaceutical company dedicated to developing breakthrough therapies for severe diseases. Its strategy involves leveraging scientific innovation and strategic partnerships to advance its pipeline efficiently. Its competitive advantage lies in its targeted approach to specific disease areas and its experienced management team.
Total Addressable Market (TAM)
The TAM for pulmonary arterial hypertension and rare fibrotic lung diseases is substantial and growing, driven by increasing disease prevalence and an aging population. ArriVent BioPharma's positioning aims to capture a significant portion of this market by offering novel and effective treatment options for these conditions.
Upturn SWOT Analysis
Strengths
- Focused pipeline targeting significant unmet medical needs.
- Experienced management team with a track record in biopharmaceutical development.
- Innovative scientific approach to drug discovery.
- Potential for strong intellectual property protection.
Weaknesses
- Early-stage company with no approved products.
- Dependence on clinical trial success.
- Limited financial resources compared to established pharmaceutical giants.
- Need for significant capital to fund ongoing research and development.
Opportunities
- Growing demand for treatments for pulmonary and rare diseases.
- Potential for strategic partnerships and collaborations.
- Advancements in genetic and molecular research enabling novel therapeutic targets.
- Expansions into new therapeutic areas or geographical markets.
Threats
- Clinical trial failures or delays.
- Regulatory hurdles and rejections.
- Intense competition from established and emerging biopharmaceutical companies.
- Pricing pressures and reimbursement challenges.
- Intellectual property challenges or patent expirations.
Competitors and Market Share
Key Competitors
- Bristol Myers Squibb (BMY)
- United Therapeutics Corporation (UTHR)
- Bayer AG (BAYN.DE)
- Pfizer Inc. (PFE)
- Boehringer Ingelheim (Private)
- Genentech (owned by Roche, RHHBY)
Competitive Landscape
ArriVent BioPharma operates in a competitive landscape dominated by larger, established pharmaceutical companies with significant resources. ArriVent's advantage lies in its focused approach and potentially disruptive novel mechanisms of action. However, it faces challenges in terms of R&D funding, clinical trial execution, and the scale of commercialization compared to its peers.
Growth Trajectory and Initiatives
Historical Growth: ArriVent BioPharma's historical growth has been primarily characterized by the advancement of its product pipeline from preclinical to clinical stages and by its successful capital-raising efforts to fund these advancements.
Future Projections: Future growth projections are contingent on the successful clinical development and regulatory approval of its lead product candidates. Analyst estimates, if available, would focus on projected peak sales and market penetration post-launch, heavily dependent on clinical outcomes.
Recent Initiatives: Recent initiatives include the progression of AVR-RD-01 into clinical trials, ongoing research for AVR-421, and securing financing to support these development activities.
Summary
ArriVent BioPharma is an early-stage company with a promising pipeline in critical areas like pulmonary and rare diseases. Its strengths lie in its focused strategy and experienced team, while its primary weaknesses are its lack of approved products and dependence on clinical success and funding. Significant opportunities exist due to unmet medical needs, but it must navigate intense competition and regulatory hurdles. The company needs to closely monitor clinical trial progress and secure adequate funding to bring its therapies to market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q, S-1)
- Financial News Outlets (e.g., Bloomberg, Reuters, Wall Street Journal)
- Industry Analysis Reports
- Company Investor Relations Materials
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Investors should conduct their own due diligence before making any investment decisions. Market share data for early-stage companies is often estimated or based on projected potential.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ArriVent BioPharma, Inc. Common Stock
Exchange NASDAQ | Headquaters Newtown Square, PA, United States | ||
IPO Launch date 2024-01-26 | Co-Founder, Chairman, President & CEO Dr. Zhengbin Yao Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 52 | Website https://arrivent.com |
Full time employees 52 | Website https://arrivent.com | ||
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.